tetano
Editor, Senior Moderator
J Infect Dis. 2013 Dec 19. [Epub ahead of print]
Antibody response to influenza A (H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.
Gaglani M, Spencer S, Ball S, Song J, Naleway A, Henkle E, Bozeman S, Reynolds S, Sessions W, Hancock K, Thompson M.
Author information
Abstract
Background. Few data are available on the immunogenicity of repeated annual doses of influenza A(H1N1)pdm09-containing vaccines.Methods. We enrolled healthcare personnel (HCP) in direct patient-care during Fall 2010 at 2 centers with voluntary immunization. We verified the receipt of A(H1N1)pdm09-containing monovalent inactivated influenza vaccine (MIIV) and 2010-2011 trivalent inactivated vaccine (TIV). We performed hemagglutination-inhibition antibody (HI) assays on pre-season, post-TIV, and end-of-season sera. We compared the proportion of HCPs with HI titer ≥40 (HI≥40) against A(H1N1)pdm09 per receipt of prior-season-MIIV, current-season-TIV, both, or neither.Results. At pre-season (N=1,417), HI≥40 was significantly higher among those who received MIIV (34%) vs. those who did not (14%), adjusted-Relative Risk (ARR) (95% Confidence Interval (CI)): 3.26 (2.72-3.81). At post-TIV (N=865), HI≥40 was lower among HCP who received MIIV and TIV (66%) than among those receiving only TIV (85%), ARR (95% CI): 0.93 (0.84-0.997). At end-of-season (N=1,254), HI≥40 was 40% among those who received both MIIV and TIV and 67% among those receiving only TIV, ARR (95% CI): 0.76 (0.65-0.88); 52% among those who received MIIV only, and 12% among those receiving neither.Conclusions. HCP immunization programs should consider effects of host immune-response and vaccine antigenic-distance on immunogenicity of repeated annual doses of influenza vaccines.
PMID:
24363436
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24363436
Antibody response to influenza A (H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.
Gaglani M, Spencer S, Ball S, Song J, Naleway A, Henkle E, Bozeman S, Reynolds S, Sessions W, Hancock K, Thompson M.
Author information
Abstract
Background. Few data are available on the immunogenicity of repeated annual doses of influenza A(H1N1)pdm09-containing vaccines.Methods. We enrolled healthcare personnel (HCP) in direct patient-care during Fall 2010 at 2 centers with voluntary immunization. We verified the receipt of A(H1N1)pdm09-containing monovalent inactivated influenza vaccine (MIIV) and 2010-2011 trivalent inactivated vaccine (TIV). We performed hemagglutination-inhibition antibody (HI) assays on pre-season, post-TIV, and end-of-season sera. We compared the proportion of HCPs with HI titer ≥40 (HI≥40) against A(H1N1)pdm09 per receipt of prior-season-MIIV, current-season-TIV, both, or neither.Results. At pre-season (N=1,417), HI≥40 was significantly higher among those who received MIIV (34%) vs. those who did not (14%), adjusted-Relative Risk (ARR) (95% Confidence Interval (CI)): 3.26 (2.72-3.81). At post-TIV (N=865), HI≥40 was lower among HCP who received MIIV and TIV (66%) than among those receiving only TIV (85%), ARR (95% CI): 0.93 (0.84-0.997). At end-of-season (N=1,254), HI≥40 was 40% among those who received both MIIV and TIV and 67% among those receiving only TIV, ARR (95% CI): 0.76 (0.65-0.88); 52% among those who received MIIV only, and 12% among those receiving neither.Conclusions. HCP immunization programs should consider effects of host immune-response and vaccine antigenic-distance on immunogenicity of repeated annual doses of influenza vaccines.
PMID:
24363436
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24363436